Aphasia, Conduction: Clinical Trials

2 trials for Aphasia, Conduction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable1Completed 1
Phase 21Recruiting 1

Follow Aphasia, Conduction: new trials by email Literature Review of Aphasia, Conduction trials Research Report on Aphasia, Conduction

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)
Semantic Feature Analysis (traditional), Semantic Feature Analysis + Metacognitive Strategy Training - Aphasia, Aphasia Following Cerebral Infarction
Phase 2RecruitingTeachers College, Columbia University402025-07-282026-06-25
Modeling Treated Recovery From Aphasia
Semantically focused treatment, Phonologically focused treatment - Aphasia, Stroke
Not applicableCompletedUniversity of South Carolina1272016-08-022022-04-28

Narrower conditions

Anomia (2)  ·  Aphasia (2)  ·  Aphasia, Broca (2)  ·  Stroke (2)  ·  Aphasia, Wernicke (1)  ·  Communication (1)  ·  Ischemic Stroke (1)  ·  Language (1)

Broader conditions

Brain Diseases (2)  ·  Cardiovascular Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Cerebrovascular Disorders (2)  ·  Communication Disorders (2)  ·  Language Disorders (2)  ·  Nervous System Diseases (2)  ·  Neurobehavioral Manifestations (2)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Speech Disorders (2)  ·  Vascular Diseases (2)  ·  Behavior (1)

Sponsors

Teachers College, Columbia University (1)  ·  University of South Carolina (1)

Countries

United States (2)

Top investigators

Julius Fridriksson, PhD, CCC-SLP (1)

Results publications

PMID 36526425, PMID 41203433

NIH funding

P50DC014664 (1)